Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today

Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include:

Clinical trial updates and discussion of how findings may translate into clinical practice and FDA approvals Treatment sequencing and patient selection Step-up dosing and what to expect in terms of toxicity management when using a GPRC5D-targeted therapy with on-target, off-tumor effects

Presenters:

Jesus Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research 
Partner
Tennessee Oncology
Nashville, Tennessee

Amrita Krishnan, MD, FCAP
Nason Hollingworth Family Chair in Myeloma
Director, Judy and Bernard Briskin Center for Myeloma
Professor Hematology/HCT
Executive Director of Hematology
City of Hope Orange County
Irvine, California

Content based on an online CME program supported by an educational grant from Johnson & Johnson.

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.